Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies.

scientific article published on January 2009

Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1002/ART.24232
P698PubMed publication ID19116963
P5875ResearchGate publication ID23714165

P50authorMaria G TektonidouQ57034988
Haralampos MoutsopoulosQ87896552
Demosthenes B. PanagiotakosQ87944029
P2093author name stringKaterina Laskari
P2860cites workPrognostic factors and clustering of serious clinical outcomes in antiphospholipid syndromeQ33333387
Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significanceQ33392960
Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in miceQ41927420
Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosisQ48394757
P433issue1
P921main subjectsystemic lupus erythematosusQ1485
thrombosisQ261327
P304page(s)29-36
P577publication date2009-01-01
P1433published inArthritis and RheumatismQ23929027
P1476titleRisk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies
P478volume61

Reverse relations

cites work (P2860)
Q53245134A 26-year-old white man with a systemic lupus erythematosus flare and acute multiorgan ischemia: Vasculitis or thrombosis?
Q42830956Acquired hemophilia A and von Willebrand syndrome in a patient with late-onset systemic lupus erythematosus
Q34069117Annexin A5 anticoagulant activity in children with systemic lupus erythematosus and the association with antibodies to domain I of β2-glycoprotein I.
Q90264610Anti-RNP/Sm antibodies in patients with systemic lupus erythematosus and its role in thrombosis: a case-control study
Q64956251Antimalarials - are they effective and safe in rheumatic diseases?
Q35756040Antiphospholipid Syndrome during pregnancy: the state of the art
Q55891386Antiphospholipid syndrome
Q64046338Antiphospholipid syndrome
Q37721617Antiphospholipid syndrome treatment beyond anticoagulation: are we there yet?
Q38679842Antiphospholipid syndrome: an update for clinicians and scientists
Q36477921At the Bench: Neutrophil extracellular traps (NETs) highlight novel aspects of innate immune system involvement in autoimmune diseases
Q35008643Autoimmunity and recurrent pregnancy losses
Q90415557Cerebrovascular Events in Systemic Lupus Erythematosus: Diagnosis and Management
Q57807704Chloroquine attenuates TLR3-mediated plasminogen activator inhibitor-1 expression in cultured human glomerular endothelial cells
Q38994352Clinical characteristics and laboratory findings of 252 Chinese patients with anti-phospholipid syndrome: comparison with Euro-Phospholipid cohort
Q42269209Continous Rituximab treatment for recurrent diffuse alveolar hemorrhage in a patient with systemic lupus erythematosus and antiphosholipid syndrome
Q37642830Current management of antiphospholipid syndrome-related thrombosis
Q51252221Discontinuation of anticoagulation or antiaggregation treatment may be safe in patients with primary antiphospholipid syndrome when antiphospholipid antibodies became persistently negative.
Q26771128Do neutrophil extracellular traps contribute to the heightened risk of thrombosis in inflammatory diseases?
Q37721607Domain I of beta2-glycoprotein I: its role as an epitope and the potential to be developed as a specific target for the treatment of the antiphospholipid syndrome
Q44220064Dyslipidaemia in patients with lupus nephritis.
Q34161393Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort
Q53190790Effects of statins on thrombosis development in patients with systemic lupus erythematosus and antiphospholipid antibodies.
Q38745362Effects of synthetic and biological disease modifying antirheumatic drugs on lipid and lipoprotein parameters in patients with rheumatoid arthritis
Q50737245Elevated partial antiphospholipid score is a strong risk factor for thrombosis in patients with systemic lupus erythematosus: a validation study.
Q38782057Emerging Therapies in Antiphospholipid Syndrome
Q41914711Factors Related to Blood Hydroxychloroquine Concentration in Patients With Systemic Lupus Erythematosus
Q37399457Gastric mucosal injury in systemic lupus erythematosus patients receiving pulse methylprednisolone therapy
Q48459103Haralampos M. Moutsopoulos: A lifetime in autoimmunity
Q38663014How to Identify High-Risk APS Patients: Clinical Utility and Predictive Values of Validated Scores
Q64069038Hydroxychloroquine for prevention of recurrent miscarriage: study protocol for a multicentre randomised placebo-controlled trial BBQ study
Q47680027Hydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease.
Q58608546Hydroxychloroquine partially prevents endothelial dysfunction induced by anti-beta-2-GPI antibodies in an in vivo mouse model of antiphospholipid syndrome
Q33747286Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug
Q34003992Hydroxychloroquine reduces binding of antiphospholipid antibodies to syncytiotrophoblasts and restores annexin A5 expression
Q41934841Hydroxychloroquine: a new therapeutic approach to the thrombotic manifestations of antiphospholipid syndrome
Q37827403Hydroxychloroquine: from malaria to autoimmunity
Q38856073IgG/IgM antiphospholipid antibodies present in the classification criteria for the antiphospholipid syndrome: a critical review of their association with thrombosis
Q38883883Immunomodulators in SLE: Clinical evidence and immunologic actions
Q38826804Immunotherapeutic strategies in antiphospholipid syndrome
Q35711767Influenza vaccination can induce new-onset anticardiolipins but not β2-glycoprotein-I antibodies among patients with systemic lupus erythematosus
Q40725518Low-dose aspirin as primary prophylaxis for cardiovascular events in systemic lupus erythematosus: a long-term retrospective cohort study
Q51332462Lupus anticoagulant: a marker for stroke and venous thrombosis in primary Sjögren's syndrome.
Q26774815Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives
Q33730536Management of cardiovascular complications in systemic lupus erythematosus
Q38180647Management of recurrent thrombosis in antiphospholipid syndrome
Q64910478Management of thrombotic and obstetric antiphospholipid syndrome: a systematic literature review informing the EULAR recommendations for the management of antiphospholipid syndrome in adults.
Q90289969Multiple embolic strokes as a result of Libman-Sacks endocarditis associated with lupus and secondary antiphospholipid antibody syndrome: a case report
Q39440991New Insights on Platelets and Platelet-Derived Microparticles in Systemic Lupus Erythematosus.
Q38026787New insights into mechanisms of therapeutic effects of antimalarial agents in SLE.
Q34140319New therapeutic targets for the antiphospholipid syndrome
Q55440072Nonbacterial thrombotic endocarditis in a patient with primary antiphospholipid syndrome.
Q50052184Novel Insights in Systemic Lupus Erythematosus and Atherosclerosis.
Q33574487Pathogenesis, diagnosis and management of neuropsychiatric SLE manifestations
Q36966870Peptidylarginine deiminase inhibition is immunomodulatory and vasculoprotective in murine lupus
Q52349399Perioperative Management of Patients with Inflammatory Rheumatic Diseases Undergoing Major Orthopaedic Surgery: A Practical Overview.
Q39138695Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study
Q38794847Prevention of Recurrent Thrombosis in Antiphospholipid Syndrome: Different from the General Population?
Q24633010Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Q39027911Prevention of thrombosis in antiphospholipid syndrome
Q37812011Primary Thrombosis Prophylaxis in Antiphospholipid Antibody–Positive Patients: Where Do We Stand?
Q48274065Primary prevention of cardiovascular disease in patients with systemic lupus erythematosus: case series and literature review.
Q38392607Primary prophylaxis to prevent obstetric complications in asymptomatic women with antiphospholipid antibodies: a systematic review
Q33692770Review on Effectiveness of Primary Prophylaxis in aPLs with and without Risk Factors for Thrombosis: Efficacy and Safety
Q35925359Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE.
Q53113544Solid Phase Immunoassay for the Detection of Anticardiolipin Antibodies.
Q88399624The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody-Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository
Q37721612The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and thrombosis
Q38873953The antiphospholipid syndrome: from pathophysiology to treatment.
Q38680580The association between ABO blood types and venous thromboembolism in individuals with a positive antiphospholipid profile is varied by sex.
Q28072610The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus
Q38257820The clinical utility of anti-ribosomal P autoantibodies in systemic lupus erythematosus
Q38125246The current standing of diagnosis of antiphospholipid syndrome associated with systemic lupus erythematosus
Q94672281The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis?
Q37947108The role of antimalarial agents in the treatment of SLE and lupus nephritis
Q33904653The role of neutrophils and NETosis in autoimmune and renal diseases
Q36147794Thrombosis in systemic lupus erythematosus: a review article
Q37642828Thrombosis in systemic lupus erythematosus: risk and protection
Q38135335Top 10 clinical research developments in antiphospholipid syndrome
Q38149851Transient ischemic attack and stroke in systemic lupus erythematosus
Q38205079Treat-to-target in systemic lupus erythematosus: recommendations from an international task force.
Q35621012Treatment of Thrombotic Antiphospholipid Syndrome: The Rationale of Current Management-An Insight into Future Approaches
Q37803363Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients
Q39027915What is the role of hydroxychloroquine in reducing thrombotic risk in patients with antiphospholipid antibodies?
Q90416101[Antiphospholipid syndrome : Update on diagnostics and management]
Q87831212[Antiphospholipid syndrome]
Q41375519β2-Glycoprotein I-Dependent Anti-Cardiolipin Antibodies Associated With Periodontitis in Patients With Systemic Lupus Erythematosus.

Search more.